Download het volledig rapport (302 p.) - KCE

More documents

Recommendations

Info

KCE reports vol. 6A Prenatale zorg 134 Study Ref Population Intervention Outcomes mother-to-child Results Comments Study type transmission with no Reduction of risk of antiretroviral mother-to-child treatment and vaginal transmission with no or emergency antiretroviral treatment caesarean section vs. and vaginal or emergency elective caesarean caesarean section vs. section and elective caesarean section antiretroviral therapy and antiretroviral therapy: 31.6% (13.6% to 52.2%) to 4.2% (0.8% to 8.5%) Short short (treatment with zidovudine) = 35 weeks in pregnancy for mother and until 3 days old for baby Long long (treatment with zidovudine) = from 28 weeks in pregnancy for mother and for the baby until 6 weeks old Long short (treatment with zidovudine) = from 28 weeks pregnancy for the mother and for the baby until it is 3 days old Short long (treatment with zidovudine) = from 35 weeks in pregnancy for the mother and for the baby until 6 weeks old Does screening for HIV in pregnancy and instituting appropriate interventions lead to improved maternal and perinatal outcomes? Study Ref Population Intervention Outcomes Results Comments Study Brocklehurst and Volmink, 2002 4 [416] 8 RCTs total, various countries, HIV infected, pregnant women Cochrane review Most recent update 2002 Zidovudine vs. placebo Zidovudine vs.zidovudine Short short vs. longlong Long short vs. long long Short long vs. long long Infant death within 1 year of birth (n=1487, 4RCT´s) Infant death within 28 days of birth (n = 1210, 3 RCTs) Infant death after 1 year of birth (n = 395, 1 RCT) Incidence of stillbirth (n = 1504, 4 RCTs) OR 0.57 (95% CI 0.38 to 0.85) OR 1.87 (95% CI 0.68 to 5.10) OR 1.02 (95% CI 0.14 to 7.28) OR 0.83 (95% CI 0.36 to 1.92) * Significant heterogenity between RCTs ** Number of maternal deaths small and wide CIs *** This study was double-blind with central randomisation EL EL type SR 1a
KCE reports vol. 6A Prenatale zorg 135 Study Ref Population Intervention Outcomes Results Comments Study type EL Nevirapine vs. Incidence of preterm OR 0.86 (95% CI 0.57 to and a nonbreastfeeding zidovudine delivery (n = 757, 2 RCTs) 1.29) population. Incidence of low birth OR 0.74 (95% CI 0.53 to 2% lost to follow-up weight (n = 1192, 3 RCTs) 1.04) Any side effects in child OR 1.27 (95% CI 0.87 to (n = 1480, 4 RCTs) 1.87) Sufficient side effects in OR 1.02 (95% CI 0.43 to child to stop or change treatment (n = 415, 1 RCT) 2.40) Maternal death (n = OR 0.30 (95% CI 0.13 to 1391, 4 RCTs)** 0.68 Any side effect in OR 1.01 (95% CI 0.66 to mother (n = 1085, 3 RCTs) 1.53) Sufficient side effects in OR 1.42 (95% CI 0.64 to mother to change or stop treatment (n = 1506, 4 RCTs) 3.18) Infant death within 1 OR 1.93 (95% CI 0.35 to year of birth (n = 434, 1 10.63) RCT)*** Infant death within 28 OR 1.94 (95% CI 0.17 to days of birth (n = 454, 1 RCT) 21.54) Incidence of stillbirth (n OR 1.92 (95% CI 0.17 to = 454, 1RCT) 21.35) Incidence of preterm OR 0.47 (95% CI 0.16 to delivery (n = 454, 1 RCT) 1.39)
Page 1 and 2:
NATIONALE RICHTLIJN PRENATALE ZORG:
Page 3 and 4:
Nationale richtlijn prenatale zorg:
Page 5 and 6:
KCE reports vol. 6A Prenatale zorg
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114: KCE reports vol. 6A Prenatale zorg
Page 163: KCE reports vol. 6A Prenatale zorg
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
This page is left intentionally bla
Page 301:
KCE reports 1. Effectiviteit en kos
show all

Download het volledig rapport (302 p.) - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?